{
    "Trade/Device Name(s)": [
        "ADVIA Centaur CA 125II",
        "ADVIA Centaur\u00ae CA 125II"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics, Inc.",
    "510(k) Number": "K200199",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020828"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LTK"
    ],
    "Summary Letter Date": "April 6, 2020",
    "Summary Letter Received Date": "January 27, 2020",
    "Submission Date": "April 3, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Cancer Antigen 125 (CA 125)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (Lithium Heparin)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur XP",
        "ADVIA Centaur XPT",
        "ADVIA Centaur Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Direct Chemiluminescence Immunoassay",
        "Two-site sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for the ADVIA Centaur CA 125II chemiluminescent immunoassay for quantitative measurement of CA 125 in serum and plasma on ADVIA Centaur platforms.",
    "Indications for Use Summary": "For in vitro quantitative, serial determination of CA 125 in human serum and plasma to aid in monitoring and managing patients previously treated for ovarian cancer using ADVIA Centaur XP and XPT systems; not for screening or diagnosis.",
    "fda_folder": "Immunology"
}